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T
ype2diabetes,amajorpublichealth
problem of great concern, affects
millions of patients in both devel-
opedanddevelopingcountries.Thesepa-
tients run a well-documented increased
risk of cardiovascular disease (CVD), the
risk of which is two- to threefold greater
thanthatseeninnondiabeticsubjects(1).
Despite modern methods for treatment of
diabetes and its risk factors and compli-
cations, the increased risk is still substan-
tial. This is so even if data on risk factor
control in national surveys, repeated on
an annual basis, have shown improving
trends for blood pressure and lipid con-
trol,e.g.,intheNationalDiabetesRegister
in Sweden (2). Because hypertension and
lipid disturbances are currently relatively
easy to treat pharmacologically, this de-
notes that the majority of patients with
diabetes are also to some extent receiving
treatment for their CVD risk factors. Ide-
ally, only studies that could prove the ef-
fect on clinical end points should be
accepted as fundamental for evidence-
based medicine in national or interna-
tional guidelines. However, in addition,
intermediate end points have been advo-
cated for evaluation of intervention ef-
fects, as recently shown in studies
evaluating drug effects on carotid or cor-
onary atherosclerosis. This has provoked
a clinical debate as that related in the fol-
lowing two sets of arguments, i.e., pro or
con regarding the use of intermediate end
points when hypertension in diabetes is
treated.
On the pro side, arguments are con-
centrated in defense of using left ventric-
ularhypertrophy,albuminuria,orarterial
stiffness as useful surrogate markers, or
intermediary end points, to guide the in-
tensity and mode of treatment. However,
on the con side, other more critical argu-
ments are given to state that only drugs
that are also able to decrease the rate of
clinical events should be used, e.g., those
showntoreduceCVD,includingmyocar-
dialinfarctionandstroke,andinaddition
also end-stage renal disease. These argu-
ments were debated in Barcelona at the
Controversies in Obesity, Diabetes, and
Hypertension (CODHy) symposium on 1
November 2008 and are summarized
here.
One study that showed a decrease in
both intermediate end points and cardio-
vascular events is the successful long-
termfollow-upoftheDanishSteno-2trial
(3). In that study, patients with type 2
diabetes and microalbuminuria, and
many with concomitant hypertension,
were vigorously treated for optimal risk
factor control, with proven beneﬁts after
more than 13 years of follow-up. There-
fore, both types of end points should ide-
ally be ready to be evaluated within one
and the same trial. However, not all trials
could provide such excellent conditions
as the Steno-2 trial (3) and, therefore, a
clinical controversy exists. Should we, or
should we not, rely on intermediate end
point evaluation in clinical decision mak-
ing? That is the question.
Patients with type 2 diabetes run an
increased risk of CVD, sometimes de-
scribed as equivalent to a state of post–
myocardial infarction in nondiabetic
subjects (4,5). The prominent CVD risk
factors to detect, treat, and follow up are
elevated blood pressure levels, hypercho-
lesterolemia (with elevated LDL choles-
terol), dyslipidemia (high triglycerides,
lowHDLcholesterol),aswellashypergly-
cemia and smoking. In addition, chronic
inﬂammation and defects in ﬁbrinolytic
function as well as adverse psychosocial
conditions could all contribute to this in-
creased risk, besides the impact of back-
ground factors that are impossible to
change,suchasage,sex,anddiabetesdu-
ration. Because type 2 diabetes and its as-
sociated risk factors could be seen as a
model of early vascular aging (EVA) (6),
this implies that surrogate markers of this
process can also be measured. Some ex-
amples are intima-media thickness after
ultrasound evaluation of arteries, coro-
nary calciﬁcation via magnetic resonance
imaging, increased pulse wave velocity
(PWV), decreased ankle-brachial blood
pressure index, impaired renal function,
and (micro-) albuminuria (7). It has been
argued that it is enough to measure these
markers for clinical evaluation of effects.
However, ultimately of greatest impor-
tance,accordingtotheconceptofPatient-
Oriented End points that Matter (POEM)
(8), is to decrease the risk of diabetes-
related complications and mortality risk.
This can only be achieved via long-term
randomized controlled trials, sometimes
combined for a meta-analysis, as was re-
cently shown for the beneﬁts of statin
therapy in patients with diabetes (9). The
proven risk factors that should be ad-
dressed by interventions are hyperten-
sion,hyperlipidemia,hyperglycemia,and
smoking, as evidenced in the observa-
tional part of the U.K. Prospective Diabe-
tes Study (UKPDS) (10).
GUIDELINES ARE BASED
ON EVIDENCE FROM
LARGE TRIALS— For several years,
data have accumulated on treatment ben-
eﬁts of control of these major risk factors
based on reports from large-scale clinical
trials involving patients with type 1 dia-
betes(i.e.,theDiabetesControlandCom-
plications Trial) or type 2 diabetes (i.e.,
UKPDS, Reduction of Endpoints in
NIDDM with the Angiotensin II Antago-
nistLosartan[RENAAL],IrbesartaninDi-
abetic Nephropathy Trial [IDNT], Heart
Protection Study [HPS], Collaborative
Atorvastatin Diabetes Study [CARDS],
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duction in hypertension [LIFE], Anglo-
Scandinavian Cardiac Outcomes Trial
[ASCOT], Ongoing Telmisartan Alone
and in combination with Ramipril
Global Endpoint Trial [ONTARGET],
Avoiding Cardiovascular events through
Combination therapy in Patients Liv-
ing with Systolic Hypertension Trial
[ACCOMPLISH]). Hence, to date, we have
had strong support for some, but not all,
ofthegoalsforriskfactorcontrolstatedin
contemporary guidelines for treatment of
patients with diabetes, jointly from both
the American Diabetes Association and
American Heart Association (11). This is
also true for the corresponding joint
guideline from the European Society of
Cardiology and the European Association
for the Study of Diabetes (12). For exam-
ple, the recommended goal of blood
pressure control in patients with diabe-
tes and hypertension (130/80 mmHg)
(4,11,12)wasnotbasedonsolidevidence
from intervention studies, but from ob-
servationalstudies.Thiswasmostnotably
from the observational arm of UKPDS,
where a linear association between sys-
tolic blood pressure and risk of coronary
artery disease was noticed (13). Ideally, it
takes a multiple risk factor control ap-
proach to show real health beneﬁts, as
was recently reported from the long-term
follow-up (13.8 years) analysis of the
Steno-2studyinDenmark(3).Inthisran-
domized controlled trial, patients with
the combination of type 2 diabetes and
microalbuminuria, many also being hy-
pertensive, were randomized to either in-
tensive risk factor control or to standard
therapy. The basis for intensive interven-
tion was a wide prescription of ACE in-
hibitors and statins, as well as other
preventive drug medications. It tran-
spiredthatsuchtherapyleadtoadecrease
not only in diabetes-related cardiovascu-
larendpoints,butalsoreducedtotalmor-
tality by 50%. These impressive results
were gained after a long-term post-trial
follow-up and further extended the re-
sults obtained during the 5 years of the
main trial (3). Thus, the Steno-2 trial pro-
vides evidence for not only the random-
ized controlled trial design as the most
effective model, but also for the objective
to strive for hard end points (POEM) (8)
and not to use surrogates, e.g., concen-
trating on the changes in microalbumin-
uria. These changes are themselves
noteworthyandhaveindeedbeenusedin
other studies (14), but can never replace
the far more important major clinical
CVD end points.
LESSONS FROM
INTERVENTION TRIALS OF
BLOOD PRESSURE
CONTROL— Important new evi-
dence has been published based on data
from two large-scale intervention studies
(ADVANCE and ACCOMPLISH) aiming
at controlling blood pressure in patients
with type 2 diabetes (15,16) . The multi-
center international ADVANCE trial
studiedtheeffectsoftheroutineadmin-
istration of a ﬁxed ACE inhibitor–
diuretic combination on serious vascular
events in patients with diabetes, irrespec-
tive of initial blood pressure levels, or the
use of other blood pressure–lowering
drugs. The trial was performed by 215
collaborating centers in 20 countries. Af-
ter a 6-week active run-in period, 11,140
patients with type 2 diabetes were ran-
domized to treatment with a ﬁxed combi-
nation of perindopril and indapamide or
matching placebo, in addition to current
therapy for CVD risk factor control. The
primary end points were composites of
major macrovascular and microvascular
events, deﬁned as death from CVD, non-
fatal stroke or nonfatal myocardial infarc-
tion, and new or worsening renal or
diabetic eye disease. All analyses were
madebyintentiontotreat.Themacrovas-
cular and microvascular composites were
analyzed jointly and separately. After a
mean4.3yearsoffollow-up,73%ofthose
assigned active treatment and 74% of
those assigned placebo remained on their
randomized treatment. Compared with
patients assigned placebo, those assigned
active therapy had a mean reduction in
bloodpressureof5.6/2.2mmHg.Therel-
ative risk of a major macrovascular or mi-
crovascular event was reduced by 9%
(861 [15.5%] active vs. 938 [16.8%] pla-
cebo; hazard ratio [HR] 0.91, 95% CI
0.83–1.00, P  0.04). The separate re-
ductions in macrovascular and microvas-
cular events were similar, but were not
independently signiﬁcant. The relative
risk of death from CVD was reduced by
18% (0.82% CI 0.68–0.98, P  0.03)
and all-cause mortality was reduced by
14%(0.86%CI0.75–0.98,P0.03).No
evidence was found that the effects of the
study treatment differed by initial blood
pressurelevelorconcomitantuseofother
treatments at baseline (15).
Therefore,theauthorsconcludedthat
theroutineadministrationofaﬁxedcom-
bination of perindopril and indapamide
to patients with type 2 diabetes was well
tolerated and reduced the risks of major
vascular events, including death. Al-
though the conﬁdence limits were wide,
the results suggest that over a 5-year pe-
riod,onedeathduetoanycausewouldbe
averted among every 79 patients assigned
active therapy. However, in an accompa-
nyingeditorialbyNormanKaplan(17),it
was mentioned that probably other com-
binations of antihypertensive drugs
would be able to achieve the same clinical
beneﬁts, since the blood pressure reduc-
tion per se seemed to be the most impor-
tant. Another critical question is why no
preventive effect on cerebrovascular
events (stroke) was noticed. This might
eventually be because a large proportion
ofthepatientswerealreadyonstatinther-
apy or received it during the study (45%
at follow-up) as background medication,
and it has been shown that statins con-
tribute to stroke prevention. It could be
hypothesized that, in the lower blood pres-
sure interval, as found in the ADVANCE
trial, the statin preventive effect could over-
ride the impact of blood pressure lowering
by antihypertensive drugs.
FIXED DRUG COMBINATION
BENEFITS— More recently, the AC-
COMPLISH trial provided overwhelming
evidencethatacombinationofbenazepril
(ACE inhibitor) and amlodipine (calcium
antagonist) was superior to a ﬁxed com-
bination of benazepril and hydrochlor-
thiazide in nondiabetic and diabetic
patients,inspiteofsimilarbloodpressure
reduction (16). The study was prema-
turely ended due to a pronounced differ-
ence in the composite end point of
cardiovascular morbidity and mortality
(risk ratio 0.80, 95% CI 0.72–0.90). The
results resemble the beneﬁt that was
achieved with a similar ACE inhibitor/
calcium antagonist therapy in the ASCOT
trial (18).
FAILURES TO SHOW
EFFECTS ON EARLY
ATHEROSCLEROSIS— Conversely,
it is known that two promising drugs for
metabolic control, the lipid-lowering
ezetimib and the CB1-antagonist rimon-
abant,failedtodecreaseearlysignsofath-
erosclerosis, even if LDL cholesterol and
C-reactive protein were reduced by
ezetimibaddedtosimvastatinversussim-
vastatin alone in the Ezetimibe and
Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression
(ENHANCE) study (19) or that rimon-
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lipids in the Strategy to Reduce Athero-
sclerosis Development Involving Adminis-
tration of Rimonabant–The Intravascular
Ultrasound Study (STRADIVARIUS) study
(20). The only solution to effectively evalu-
ate these two drugs, often prescribed to pa-
tients with type 2 diabetes, is to conduct a
large-scale intervention trial for clinical end
points.Thisalsopertainstoezetimib,which
is currently being tested, versus placebo
in the large-scale IMProved Reduction
of Outcomes: Vytorin Efﬁcacy Interna-
tional Trial (IMPROVE-IT) study (21),
while rimonabant was recently with-
drawn because of mental side effects. The
primary objective of IMPROVE-IT is to
evaluate the clinical beneﬁt of an
ezetimib/simvastatin combination 10/40
mgsingletablet,comparedwithsimvasta-
tin 40 mg. Clinical beneﬁts are deﬁned as
thereductionintheriskoftheoccurrence
of the composite end point of CV death,
major coronary events, and stroke (21).
It is of interest that no extra beneﬁt
was recorded, contrary to expectations,
when an angiotensin-2 receptor blocker
(telmisartan) and an ACE inhibitor
(ramipril) were combined, compared
with ramipril alone in the ONTARGET
trial(22)(Fig.1).Evenifpreviousstudies
have shown that such a combination is
able to reduce proteinuria, an intermedi-
ary end point, this could not regretfully
translate into extra clinical beneﬁt in pre-
ventionofCVD.Onthecontrary,ahigher
rate of early study termination was noted,
due to renal adverse effects in the combi-
nation arm compared with monotherapy
ramipril,adrugwellprovenintheplacebo-
controlled Heart Outcomes Prevention
Evaluation (HOPE) trial (23). After this
disturbing result, protagonists for the use
of intermediary end points will have an
even tougher task than before to substi-
tute drugs other than real cardiovascular
end points or end-stage renal disease.
TIGHT CONTROL OF
HYPERGLYCEMIA AND
MORTALITY RISK— Finally, it
came as a surprise when, recently, the
largeinterventionstudyActiontoControl
CardiovascularRiskinDiabetes(ACCORD)
was terminated because of an increased
mortality rate in the intensive treatment
arm for normalizing A1C levels to under
6% (Diabetes Control and Complications
Trial standard) (24,25). The publication
showed conﬂicting effects by treating an
intermediateendpoint,theglycemiccon-
trol (A1C), for increased total mortality
but a reduction in nonfatal events (25).
Thiswasalsoreﬂectedintheﬁndingsthat
treatment of hyperglycemia with ros-
iglitazone could in fact provoke some
aspects of CVD, e.g., congestive heart
failure, as shown in a meta-analysis
(26). This viewpoint was later chal-
lenged and debated (27).
CONCLUSIONS— In summary,
these examples all contribute to a critical
attitude toward intermediary end points
in cardiovascular prevention. In particu-
lar, the lack of effect on early signs of ath-
erosclerosis by use of metabolically active
drugs(ezetimib,rimonabant)andthefail-
ure to add extra clinical beneﬁts of the
angiotensin-2 receptor blocker–ACE-1
combination in ONTARGET are proof of
concept that nothing can substitute a
large randomized controlled end point
trial. Such a trial should have a clear-cut
and well-deﬁned primary aim to evaluate
effects on cardiovascular end points or its
corresponding renal outcome.
Patients and physicians require deﬁ-
nite end points to support and motivate
compliance with long-term drug medica-
tion. This is POEM (8), and anything else
is “ersatz” (German for substitute). Why
drinksurrogatecoffeewhenyoucanhave
the authentic tasty one?
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